Compare
iBio, Inc. vs Actinium Pharmaceuticals, Inc. vs Serina Therapeutics, Inc. vs Inovio Pharmaceuticals, Inc.
| Latest fiscal year | iBio, Inc. IBIO | Actinium Pharmaceuticals, Inc. ATNM | Serina Therapeutics, Inc. SER | Inovio Pharmaceuticals, Inc. INO |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $100.0K | $90.0K | $130.0K | $65.3K |
| Revenue growth (YoY) | -75.0% | n/a | +132.1% | -70.0% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$33.04M | -$33.89M | -$19.18M | -$84.95M |
| EPS (Diluted) | -$0.32 | -$1.09 | -$1.91 | -$1.81 |
| Operating cash flow | -$23.22M | -$24.58M | -$17.95M | -$88.63M |
| Free cash flow | -$23.80M | -$24.68M | -$18.01M | -$88.92M |
| Cash & equivalents | $56.40M | $48.00M | $3.06M | $44.27M |
| Total assets | $99.11M | $51.77M | $6.95M | $74.31M |
| Total liabilities | $13.40M | $43.94M | $6.99M | $50.21M |
| Shareholders' equity | $85.71M | $7.83M | -$37.0K | $24.10M |
| Return on year-end equity | -38.6% | -432.6% | n/a | -352.5% |
| Shares outstanding | 55.70M | 31.20M | 10.77M | 69.00M |
Revenue, most recent five fiscal years
| Fiscal year | iBio, Inc. | Actinium Pharmaceuticals, Inc. | Serina Therapeutics, Inc. | Inovio Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $100.0K Ended 2026-06-30 | $90.0K Ended 2025-12-31 | $130.0K Ended 2025-12-31 | $65.3K Ended 2025-12-31 |
| 1 year earlier | $400.0K Ended 2025-06-30 | n/a | $56.0K Ended 2024-12-31 | $217.8K Ended 2024-12-31 |
| 2 years earlier | $225.0K Ended 2024-06-30 | $81.0K Ended 2023-12-31 | $3.15M Ended 2023-12-31 | $832.0K Ended 2023-12-31 |
| 3 years earlier | $0 Ended 2023-06-30 | $1.03M Ended 2022-12-31 | $34.0K Ended 2022-12-31 | $10.26M Ended 2022-12-31 |
| 4 years earlier | $1.88M Ended 2022-06-30 | $1.14M Ended 2021-12-31 | $144.0K Ended 2021-12-31 | $1.77M Ended 2021-12-31 |